NovoCure (NVCR) Short Interest Ratio & Short Volume $19.40 +0.03 (+0.15%) Closing price 04:00 PM EasternExtended Trading$19.50 +0.10 (+0.52%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NovoCure Short Interest DataNovoCure (NVCR) has a short interest of 5.40 million shares, representing 5.45% of the float (the number of shares available for trading by the public). This marks a -0.74% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 1.14 million shares to cover all short positions.Current Short Interest5,400,000 sharesPrevious Short Interest5,440,000 sharesChange Vs. Previous Month-0.74%Dollar Volume Sold Short$94.99 millionShort Interest Ratio5.7 Days to CoverLast Record DateMay 15, 2025Outstanding Shares111,486,000 sharesFloat Size99,010,000 sharesShort Percent of Float5.45%Today's Trading Volume1,010,637 sharesAverage Trading Volume1,139,334 sharesToday's Volume Vs. Average89% Short Selling NovoCure? Sign up to receive the latest short interest report for NovoCure and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNVCR Short Interest Over TimeNVCR Days to Cover Over TimeNVCR Percentage of Float Shorted Over Time NovoCure Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20255,400,000 shares $94.99 million -0.7%5.5%5.7 $17.59 4/30/20255,440,000 shares $98.68 million +5.8%5.5%6 $18.14 4/15/20255,140,000 shares $84.60 million -5.2%5.2%5.8 $16.46 3/31/20255,420,000 shares $96.58 million +0.4%5.5%6 $17.82 3/15/20255,400,000 shares $105.25 million +3.5%5.5%5.7 $19.49 2/28/20255,220,000 shares $99.55 million +0.4%5.3%5 $19.07 2/15/20255,200,000 shares $116.90 million +4.6%5.3%4.4 $22.48 1/31/20254,970,000 shares $121.86 million +2.1%5.1%4.2 $24.52 1/15/20254,870,000 shares $128.32 million -9.8%5.0%4 $26.35 12/31/20245,400,000 shares $160.92 million +4.1%5.6%4 $29.80 Get the Latest News and Ratings for NVCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. 12/15/20245,190,000 shares $173.40 million -7.8%5.3%4 $33.41 11/30/20245,630,000 shares $112.83 million -0.7%5.8%4.5 $20.04 11/15/20245,670,000 shares $91.34 million -4.9%5.8%5.5 $16.11 10/31/20245,960,000 shares $90.47 million +3.1%6.1%5.6 $15.18 10/15/20245,780,000 shares $102.77 million +5.3%5.9%5.1 $17.78 9/30/20245,490,000 shares $85.81 million -10.2%5.6%5.4 $15.63 9/15/20246,110,000 shares $113.46 million -1.9%6.3%4.6 $18.57 8/31/20246,230,000 shares $121.11 million -3.9%6.4%4.5 $19.44 8/15/20246,480,000 shares $122.54 million -14.7%6.7%4.7 $18.91 7/31/20247,600,000 shares $173.05 million +8.3%7.8%5 $22.77 7/15/20247,020,000 shares $126.29 million +13.4%7.3%4.8 $17.99 6/30/20246,190,000 shares $106.03 million +10.7%6.4%4.2 $17.13 6/15/20245,590,000 shares $119.29 million +2.0%5.8%3.9 $21.34 5/31/20245,480,000 shares $120.61 million -2.8%5.7%3.9 $22.01 5/15/20245,640,000 shares $118.72 million No Change5.8%4.1 $21.05 4/30/20245,640,000 shares $69.03 million -6.6%5.8%4.4 $12.24 4/15/20246,040,000 shares $76.83 million +20.6%6.3%4.8 $12.72 3/31/20245,010,000 shares $78.31 million -9.6%5.2%3.6 $15.63 3/15/20245,540,000 shares $77.45 million -1.8%5.8%4.5 $13.98 2/29/20245,640,000 shares $86.35 million -8.0%5.9%4.4 $15.31 2/15/20246,130,000 shares $97.65 million +6.2%6.3%4.6 $15.93 1/31/20245,770,000 shares $80.32 million -17.0%6.0%4.2 $13.92 1/15/20246,950,000 shares $93.06 million +0.3%7.2%4.8 $13.39 12/31/20236,930,000 shares $103.46 million -2.8%7.2%5 $14.93 12/15/20237,130,000 shares $96.68 million -10.5%7.4%5 $13.56 11/30/20237,970,000 shares $97.79 million -5.0%8.3%5.5 $12.27 11/15/20238,390,000 shares $106.39 million -6.1%8.7%4.5 $12.68 10/31/20238,930,000 shares $118.77 million +6.3%9.2%4.8 $13.30 10/15/20238,400,000 shares $119.36 million +2.8%8.7%4.5 $14.21 9/30/20238,170,000 shares $131.95 million +7.8%8.5%4.2 $16.15Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 9/15/20237,580,000 shares $146.29 million -17.7%7.9%4.3 $19.30 8/31/20239,210,000 shares $203.17 million -1.8%9.6%5 $22.06 8/15/20239,380,000 shares $293.59 million +5.9%9.7%5.7 $31.30 7/31/20238,860,000 shares $289.19 million -0.2%N/A5.7 $32.64 7/15/20238,880,000 shares $354.67 million +2.0%N/A6.4 $39.94 6/30/20238,710,000 shares $361.47 million +3.7%N/A6.9 $41.50 6/15/20238,400,000 shares $368.76 million +4.0%N/A6.9 $43.90 5/31/20238,080,000 shares $580.22 million -1.2%N/A7.5 $71.81 5/15/20238,180,000 shares $636.57 million +5.8%N/A12.4 $77.82 4/30/20237,730,000 shares $509.41 million -1.9%N/A12.1 $65.90 4/15/20237,880,000 shares $494.23 million +2.1%7.6%12 $62.72 3/31/20237,720,000 shares $464.28 million -3.3%7.5%9.5 $60.14 3/15/20237,980,000 shares $523.17 million -8.4%7.7%7.8 $65.56 2/28/20238,710,000 shares $670.41 million +3.4%N/A9 $76.97 2/15/20238,420,000 shares $740.71 million +4.5%8.2%8.8 $87.97 1/31/20238,060,000 shares $734.91 million +3.9%7.8%8.5 $91.18 1/15/20237,760,000 shares $729.36 million -2.4%7.5%8.4 $93.99 12/30/20227,950,000 shares $583.13 million +2.3%7.7%9.4 $73.35 12/15/20227,770,000 shares $579.56 million -4.0%7.5%14.8 $74.59 11/30/20228,090,000 shares $621.64 million -1.3%7.9%16.6 $76.84 11/15/20228,200,000 shares $688.80 million -1.2%8.0%17.6 $84.00 10/31/20228,300,000 shares $586.48 million +4.3%8.1%18.2 $70.66 10/15/20227,960,000 shares $582.11 million +5.4%7.7%16.5 $73.13 9/30/20227,550,000 shares $573.65 million +0.3%7.3%16.7 $75.98 9/15/20227,530,000 shares $669.79 million +2.9%7.3%16 $88.95 8/31/20227,320,000 shares $601.19 million +5.5%7.1%12.9 $82.13 8/15/20226,940,000 shares $585.18 million +2.4%6.8%11.3 $84.32 7/31/20226,780,000 shares $460.97 million -1.2%6.6%10.1 $67.99 7/15/20226,860,000 shares $497.08 million +1.8%7.3%10.4 $72.46 6/30/20226,740,000 shares $468.43 million -11.1%7.5%10 $69.50 6/15/20227,580,000 shares $461.17 million -6.8%8.4%11.3 $60.84 5/31/20228,130,000 shares $653.49 million -0.3%9.0%13.5 $80.38 5/15/20228,150,000 shares $531.71 million +4.5%9.0%14 $65.24 4/30/20227,800,000 shares $597.32 million +5.1%8.7%13.2 $76.58 4/15/20227,420,000 shares $625.06 million -0.7%8.3%12.1 $84.24 3/31/20227,470,000 shares $618.89 million +2.8%8.3%10.9 $82.85 3/15/20227,270,000 shares $471.90 million +1.4%8.1%10 $64.91 2/28/20227,170,000 shares $586.94 million +0.1%8.0%10.1 $81.86 2/15/20227,160,000 shares $604.30 million +8.5%8.0%9.6 $84.40 1/31/20226,600,000 shares $453.09 million +5.1%7.4%8.7 $68.65 1/15/20226,280,000 shares $434.07 million +8.3%7.1%8.5 $69.12 12/31/20215,800,000 shares $435.46 million No Change6.5%8.9 $75.08 12/15/20215,800,000 shares $487.84 million -4.5%6.5%9.8 $84.11 11/30/20216,070,000 shares $568.39 million +5.8%6.8%10.7 $93.64 11/15/20215,740,000 shares $645.29 million +7.9%6.4%11.1 $112.42 10/29/20215,320,000 shares $545.67 million -0.4%6.0%11.9 $102.57 10/15/20215,340,000 shares $599.25 million -1.7%6.0%10.2 $112.22 9/30/20215,430,000 shares $630.80 million +0.7%6.1%10.4 $116.17 9/15/20215,390,000 shares $683.61 million -0.2%6.1%9 $126.83 8/31/20215,400,000 shares $724.73 million +0.6%6.1%8.2 $134.21Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/13/20215,370,000 shares $747.93 million +2.9%6.0%7.9 $139.28 7/30/20215,220,000 shares $803.93 million +2.4%5.9%7.2 $154.01 7/15/20215,100,000 shares $930.70 million +0.2%5.8%7.4 $182.49 6/30/20215,090,000 shares $1.13 billion -5.4%5.7%4.8 $221.82 6/15/20215,380,000 shares $1.17 billion +5.9%6.1%5.4 $216.79 5/28/20215,080,000 shares $1.04 billion +2.2%5.7%5.2 $204.00 5/14/20214,970,000 shares $860.01 million +2.1%5.6%4.6 $173.04 4/30/20214,870,000 shares $999.86 million +0.4%5.5%4.5 $205.31 4/15/20214,850,000 shares $902.10 million +2.5%5.5%4.7 $186.00 3/31/20214,730,000 shares $592.43 million +6.8%5.4%6.7 $125.25 3/15/20214,430,000 shares $612.62 million -3.9%5.1%5.7 $138.29 2/26/20214,610,000 shares $686.43 million -0.7%5.3%5.1 $148.90 2/12/20214,640,000 shares $849.49 million -5.3%5.3%4.9 $183.08 1/29/20214,900,000 shares $790.37 million -6.5%5.6%5 $161.30 1/15/20215,240,000 shares $937.65 million -2.4%6.1%4.9 $178.94 12/31/20205,370,000 shares $935.13 million -8.7%6.2%4.6 $174.14 12/15/20205,880,000 shares $993.66 million +17.8%6.8%5 $168.99 11/30/20204,990,000 shares $632.93 million -2.9%5.9%3.8 $126.84 11/15/20205,140,000 shares $639.83 million +25.1%6.1%4.5 $124.48 10/30/20204,110,000 shares $506.64 million -11.8%4.9%3.8 $123.27 10/15/20204,660,000 shares $637.58 million -12.6%5.6%4.7 $136.82 9/30/20205,330,000 shares $593.28 million +41.4%6.4%5.5 $111.31 9/15/20203,770,000 shares $393.81 million +14.6%4.5%3.4 $104.46 8/31/20203,290,000 shares $272.25 million +6.5%3.9%3.5 $82.75 8/14/20203,090,000 shares $233.88 million +0.3%3.7%3.3 $75.69 7/31/20203,080,000 shares $233.43 million -2.2%3.7%3.1 $75.79 7/15/20203,150,000 shares $200.47 million -6.8%3.8%3.1 $63.64 6/30/20203,380,000 shares $200.43 million -17.0%4.1%3.4 $59.30 6/15/20204,070,000 shares $265.85 million +9.1%4.9%4.6 $65.32 5/29/20203,730,000 shares $251.51 million -5.6%4.5%3.9 $67.43 NVCR Short Interest - Frequently Asked Questions What is NovoCure's current short interest? Short interest is the volume of NovoCure shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 5,400,000 shares of NVCR short. 5.45% of NovoCure's shares are currently sold short. Learn More on NovoCure's current short interest. What is a good short interest ratio for NovoCure? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NVCR shares currently have a short interest ratio of 6.0. Learn More on NovoCure's short interest ratio. Which institutional investors are shorting NovoCure? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NovoCure: Caption Management LLC, Walleye Trading LLC, Walleye Capital LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for NovoCure? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.45% of NovoCure's floating shares are currently sold short. Is NovoCure's short interest increasing or decreasing? NovoCure saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 5,400,000 shares, a decline of 0.7% from the previous total of 5,440,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NovoCure's float size? NovoCure currently has issued a total of 111,486,000 shares. Some of NovoCure's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NovoCure currently has a public float of 99,010,000 shares. How does NovoCure's short interest compare to its competitors? 5.45% of NovoCure's shares are currently sold short. Here is how the short interest of companies in the industry of "medical equipment" compare to NovoCure: Stevanato Group S.p.A. (5.46%), Glaukos Co. (6.49%), Inari Medical, Inc. (4.24%), iRhythm Technologies, Inc. (8.65%), Inspire Medical Systems, Inc. (11.25%), Bausch + Lomb Co. (7.03%), TransMedics Group, Inc. (25.95%), Soleno Therapeutics, Inc. (9.95%), PROCEPT BioRobotics Co. (11.27%), Envista Holdings Co. (5.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short NovoCure stock? Short selling NVCR is an investing strategy that aims to generate trading profit from NovoCure as its price is falling. NVCR shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NovoCure? A short squeeze for NovoCure occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NVCR, which in turn drives the price of the stock up even further. How often is NovoCure's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NVCR, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies STVN Short Interest Data GKOS Short Interest Data NARI Short Interest Data IRTC Short Interest Data INSP Short Interest Data BLCO Short Interest Data TMDX Short Interest Data SLNO Short Interest Data PRCT Short Interest Data NVST Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NVCR) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVCR Stock Free NVCR Stock Alerts